Clinical Trial News and Research

RSS

Breakthrough in pancreatic cancer treatment

Epeius Biotechnologies (www.epeiusbiotech.com) confirms the first real breakthrough for pancreatic cancer seen in years; publishes a landmark report of tumor-targeted Rexin-G as stand-alone therapy in chemotherapy-resistant pancreatic cancer.

14 Oct 2009

Antisense Therapeutics completes repeat-dosing toxicology studies for ATL1103

Antisense Therapeutics Limited is pleased to announce that the Company has now completed repeat-dosing toxicology studies for ATL1103 in two species -- mouse and non-human primate. Draft study reports from the study contractors in the United States have been received, and the toxicology outcomes from these studies support ANP's plans for the continued development of ATL1103.

14 Oct 2009

FDA recommends approval for UI Pharmaceuticals to manufacture an aseptically filled sterile drug product

In September 2009, the Kansas City District Office of the Food and Drug Administration (FDA) submitted a recommendation of approval to the Center for Drug Evaluation and Research for The University of Iowa Pharmaceuticals (UIP) to manufacture and test an aseptically filled, sterile prescription drug product for a commercial client. The drug product contains a new chemical entity and is a sterile solution that is aseptically filled into vials.

14 Oct 2009

Endovascular procedure for abdominal aortic aneurysm may reduce mortality rate

Patients who received the less-invasive endovascular repair of an abdominal aortic aneurysm had a lower risk of death in the first 30 days after the procedure compared to patients who an open repair, but both procedures had similar rates of death after two years, according to a study in the October 14 issue of JAMA, a theme issue on surgical care.

14 Oct 2009

Increase in adiponectin hormone levels protects against sepsis-related mortality

A hormone naturally found in the fat that surrounds the abdominal organs for the first time has been linked to death related to sepsis, surgeons reported at the 2009 Clinical Congress of the American College of Surgeons. A study exhibited at the conference showed that low levels of the hormone adiponectin placed animals at a profoundly high risk of death from a septic insult.

14 Oct 2009

Study shows elevated levels of antioxidant urate can slow the progression of Parkinson's disease

By examining data from a 20-year-old clinical trial, a research team based at the MassGeneral Institute for Neurodegenerative Diseases (MGH-MIND) and Harvard School of Public Health (HSPH), has found evidence supporting the findings of their 2008 study - that elevated levels of the antioxidant urate may slow the progression of Parkinson's disease.

14 Oct 2009

ADDF grant to support the evaluation of PPAR-sparing insulin sensitizers

Metabolic Solutions Development Company (MSDC) announced today that it has received a $100,000 grant from the Alzheimer's Drug Discovery Foundation (ADDF) to support the evaluation of PPAR-sparing insulin sensitizers as a potential treatment for Alzheimer's disease.

14 Oct 2009

Researchers to investigate an existing drug for speedy recovery of stroke patients

New research will determine whether an inexpensive drug called L-dopa, widely used in the treatment of Parkinson's disease, could also help thousands of stroke patients regain mobility and independence.

14 Oct 2009

Parkinson's patients with higher urate levels in their blood and CSF had slower functional decline

Individuals with Parkinson's disease who have higher levels of a metabolite called urate in their blood and in cerebrospinal fluid (CSF) have a slower rate of disease progression, according to a study funded by the National Institutes of Health.

14 Oct 2009

Positive results from Metabolex' Phase 1 MBX-2982 clinical trial for treating type 2 diabetes

Metabolex, Inc., a biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, announced positive results from two multiple ascending dose Phase 1 clinical trials of MBX-2982.

14 Oct 2009

Epeius Biotechnologies announces clinical study results of tumor-targeted genetic medicine

Epeius Biotechnologies Corporation today announced more stunning results of its pioneering clinical studies of Rexin-G, the world's first and, so far only, tumor-targeted genetic medicine to be validated in the clinic.

14 Oct 2009

Bladder cancer patients benefit from anticancer drug that is used to treat lung and colon malignancies: Study

An anticancer drug that is commonly used to treat lung and colon malignancies is having a benefit and potentially prolonging survival in patients with invasive bladder cancer, researchers reported at the 2009 Clinical Congress of the American College of Surgeons.

14 Oct 2009

Automotive technology used to develop a high tech medical tool

Research at the University of Warwick have taken high tech gas sensors normally used to test components for premium cars and applied the same techniques to human blood, human urine, and even cow dung samples from local cow pats.

14 Oct 2009

Breast tenderness indicates increased cancer risk among women on combination therapy

Women who developed new-onset breast tenderness after starting estrogen plus progestin hormone replacement therapy were at significantly higher risk for developing breast cancer than women on the combination therapy who didn't experience such tenderness, according to a new UCLA study.

13 Oct 2009

Clinical trial results of the LensAR Laser System to be presented at the 2009 AAO and PAAO joint meeting

LensAR, Inc., a leading developer of next generation laser technology for cataract surgery and other ocular applications, today announced that data from a recently completed clinical trial of the LensAR Laser System will be presented at the upcoming 2009 Joint Meeting of the American Academy of Ophthalmology (AAO) and Pan-American Academy of Ophthalmology (PAAO). The meeting will be held October 23 - 27, 2009 in San Francisco, CA.

13 Oct 2009

Provectus Pharmaceuticals completes initial treatment in Phase 2 trial of PH-10 for plaque psoriasis

Provectus Pharmaceuticals, Inc., a development stage oncology and dermatology biopharmaceutical company, has completed patient accrual and initial treatment in its Phase 2 trial of PH-10 for the treatment of plaque psoriasis. This milestone marks the third Phase 2 clinical trial for which Provectus has completed patient accrual since May 2009.

13 Oct 2009

SANUWAVE presents findings on extracorporeal shock wave stimulation of osteoprogenitor cells

SANUWAVE, Inc., an emerging medical technology company focused on the development and commercialization of non-invasive, biological response activating devices in the regenerative medicine area, reported that scientific findings titled “Extracorporeal Shock Wave Stimulation of Osteoprogenitor Cells” were presented at the 2009 International Bone-Tissue-Engineering Congress (“Bone-Tec”) in Hannover, Germany, which was held October 9-11, 2009.

13 Oct 2009

Onyx Pharmaceuticals signs definitive agreement to acquire Proteolix

Proteolix, Inc. today announced that it has signed a definitive agreement to be acquired by Onyx Pharmaceuticals, Inc.

13 Oct 2009

Sonitus Medical’s SoundBite hearing system ranks first on Top 10 Medical Innovations for 2010

Sonitus Medical, Inc., a medical device company developing the world's first non-surgical and removable hearing device to transmit sound via the teeth, today announced that technology it developed was ranked #1 on Cleveland Clinic's Top 10 Medical Innovations for 2010.

13 Oct 2009

FirstCare Texas to provide Vermedx Diabetes Information System to health care providers and patients

FirstCare Texas has signed a contract with Vermedx, Inc. to provide its patent-pending Vermedx Diabetes Information System (VDIS) for the use of health care providers and patients belonging to First Care Health Plan's health maintenance organization operating in Lubbock, Waco, Abilene, and Amarillo, Texas.

13 Oct 2009

Clinical Trial News and Research

Breakthrough in pancreatic cancer treatment

Antisense Therapeutics completes repeat-dosing toxicology studies for ATL1103

FDA recommends approval for UI Pharmaceuticals to manufacture an aseptically filled sterile drug product

Endovascular procedure for abdominal aortic aneurysm may reduce mortality rate

Increase in adiponectin hormone levels protects against sepsis-related mortality

Study shows elevated levels of antioxidant urate can slow the progression of Parkinson's disease

ADDF grant to support the evaluation of PPAR-sparing insulin sensitizers

Researchers to investigate an existing drug for speedy recovery of stroke patients

Parkinson's patients with higher urate levels in their blood and CSF had slower functional decline

Positive results from Metabolex' Phase 1 MBX-2982 clinical trial for treating type 2 diabetes

Epeius Biotechnologies announces clinical study results of tumor-targeted genetic medicine

Bladder cancer patients benefit from anticancer drug that is used to treat lung and colon malignancies: Study

Automotive technology used to develop a high tech medical tool

Breast tenderness indicates increased cancer risk among women on combination therapy

Clinical trial results of the LensAR Laser System to be presented at the 2009 AAO and PAAO joint meeting

Provectus Pharmaceuticals completes initial treatment in Phase 2 trial of PH-10 for plaque psoriasis

SANUWAVE presents findings on extracorporeal shock wave stimulation of osteoprogenitor cells

Onyx Pharmaceuticals signs definitive agreement to acquire Proteolix

Sonitus Medical’s SoundBite hearing system ranks first on Top 10 Medical Innovations for 2010

FirstCare Texas to provide Vermedx Diabetes Information System to health care providers and patients

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest Life Science News